Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there was little to no mention of drug pricing.
Amgen is expected to report its second-quarter financial results after the markets close on Wednesday. Will it go the same way as Gilead Sciences did earlier this week?
Chris Lange The short interest data are out for the July 15 settlement date. Short interest increased across many of these selected biotech stocks.
24/7 Wall St. has put together a preview of Alphabet, Amazon.com, Facebook and some of the other major companies reporting their quarterly results this week.
The June 30 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Credit Suisse has taken a look at which biotech companies in its coverage have the least credit given to pipeline potential at current levels.
Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health care if RBC…
The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After all, a…
The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation found itself in.
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
